Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study linked to the European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) in individuals without dementia to evaluate the additional value of quantitative amyloid imaging in determining Alzheimer's Disease (AD) dementia risk

Next Previous
Trial Profile

AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study linked to the European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) in individuals without dementia to evaluate the additional value of quantitative amyloid imaging in determining Alzheimer's Disease (AD) dementia risk

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Florbetaben F18 (Primary) ; Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Acronyms AMYPAD PNHS

    • Most Recent Events

    • 28 Sep 2023 This trial has been completed in Spain (Date of the global end of the trial: 27-Jun-2022), according to the European Clinical Trials Database record.
    • 20 Jul 2023 Results (n=1423) assessing value of amyloid-PET for predicting AD-related disease progression presented at the Alzheimer's Association International Conference 2023
    • 04 Aug 2022 Results assessing the impact of pipeline design and post-processing smoothing on Centiloid(CL) quantification from the two AMYPAD (PNHS and DPMS) trials, presented at the Alzheimer's Association International Conference 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top